We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+52.18%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$649M
AUM Growth
+$162M
Cap. Flow
+$16.8M
Cap. Flow %
2.6%
Top 10 Hldgs %
48.42%
Holding
76
New
11
Increased
16
Reduced
10
Closed
6

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$31.6M
2
ALKS icon
Alkermes
ALKS
+$17.8M
3
ARDX icon
Ardelyx
ARDX
+$15.4M
4
RGLS
Regulus Therapeutics
RGLS
+$13.3M
5
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$11.1M

Top Sells

Rank Stock Value
1
PBYI icon
Puma Biotechnology
PBYI
+$63.8M
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$16.1M
3
ARWR icon
Arrowhead Research
ARWR
+$13.3M
4
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$10.8M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$6.13M

Sector Composition

Rank Sector Weight
1 Healthcare 68.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCPT
1
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$78.6M 12.12%
641,800
-106,900
-14% -$10.8M
PBYI icon
2
Puma Biotechnology
PBYI
$402M
$41.6M 6.42%
220,000
-287,500
-57% -$63.8M
CELG
3
DELISTED
Celgene Corp
CELG
$33.6M 5.17%
+300,000
New +$31.6M
TPST icon
4
Tempest Therapeutics
TPST
$13.8M
$33M 5.09%
255
+79
+45% +$5.79M
ALKS icon
5
Alkermes
ALKS
$8.39B
$26.4M 4.06%
450,000
+350,000
+350% +$17.8M
NBIX icon
6
Neurocrine Biosciences
NBIX
$18.7B
$22.3M 3.44%
1,000,000
+150,000
+18% +$2.84M
DYAX
7
DELISTED
DYAX CORPORATION
DYAX
$21.1M 3.25%
1,500,000
– –
ARDX icon
8
Ardelyx
ARDX
$1.25B
$19.9M 3.07%
1,053,500
+664,800
+171% +$15.4M
QTNT
9
DELISTED
Quotient Limited Ordinary Shares
QTNT
$19.8M 3.05%
27,500
+15,000
+120% +$7.12M
RGLS
10
DELISTED
Regulus Therapeutics
RGLS
$17.6M 2.72%
9,167
+7,500
+450% +$13.3M
SRNE
11
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$17.6M 2.72%
1,750,000
+750,000
+75% +$3.8M
PTLA
12
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$17M 2.62%
600,000
+400,000
+200% +$11.1M
CMRX
13
DELISTED
Chimerix, Inc.
CMRX
$16.1M 2.48%
400,000
+150,000
+60% +$5.08M
BMY icon
14
Bristol-Myers Squibb
BMY
$132B
$14.8M 2.28%
250,000
+100,000
+67% +$5.64M
KITE
15
DELISTED
Kite Pharma, Inc.
KITE
$14.7M 2.27%
255,000
+155,000
+155% +$6.53M
OMER icon
16
Omeros
OMER
$863M
$14.4M 2.22%
582,300
+34,400
+6% +$627K
KPTI icon
17
Karyopharm Therapeutics
KPTI
$159M
$14.4M 2.22%
25,667
– –
KERX
18
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$14.2M 2.18%
1,000,000
– –
TSRO
19
DELISTED
TESARO, Inc.
TSRO
$11.2M 1.72%
300,000
– –
DXCM icon
20
DexCom
DXCM
$28.8B
$11M 1.7%
800,000
– –
XLRN
21
DELISTED
Acceleron Pharma
XLRN
$9.74M 1.5%
250,000
-150,000
-38% -$5.23M
BCRX icon
22
BioCryst Pharmaceuticals
BCRX
$2.35B
$9.73M 1.5%
800,000
-300,000
-27% -$3.31M
GEVA
23
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$9.28M 1.43%
100,000
– –
NVAX icon
24
Novavax
NVAX
$1.22B
$8.89M 1.37%
75,000
– –
SGMO
25
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$7.61M 1.17%
500,000
– –
1
2 3

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q4 2014 Portfolio in Review

As of Q4 2014, Cormorant Asset Management held 76 positions worth $649M, up 33% from $486M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Cormorant Asset Management's Q4 2014 filing shows 11 new, 16 increased, 10 reduced and 6 closed positions. Its largest new stake was Celgene Corp: 300,000 shares worth $33.6M. The largest sale was Puma Biotechnology, an estimated $63.8M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 79% a quarter earlier.

  • Cormorant Asset Management's largest Q4 2014 buy was Celgene Corp: 300,000 shares worth $33.6M.
  • Cormorant Asset Management added most to Alkermes in Q4 2014, an estimated $17.8M increase.
  • Cormorant Asset Management's biggest Q4 2014 reduction was Puma Biotechnology, cutting an estimated $63.8M.
  • Cormorant Asset Management fully exited Jazz Pharmaceuticals in Q4 2014, selling an estimated $16.1M.
  • Cormorant Asset Management's ten largest holdings make up 48% of its $649M portfolio in Q4 2014.
  • Cormorant Asset Management opened 11 new positions and closed 6 in Q4 2014.
  • Cormorant Asset Management's portfolio value rose 33% quarter-over-quarter to $649M.

Based on Cormorant Asset Management's 13F filing for Q4 2014, filed 17 Feb 2015.